INTERVIEW - Doctor Dennis Slamon talks about research that has received funds from this event at 16th Annual EIF Revlon

The video discusses a run-walk program that supports research benefiting women with breast and ovarian cancer. It highlights the program's impact on cancer trials and the significant funding from EIF and Revlon, which has led to advancements in breast cancer research, particularly in the HER2 subtype. The video also introduces new therapies for hormone-receptive breast cancer, emphasizing the importance of tailoring treatments to specific subtypes.

What is the primary purpose of the run-walk event mentioned in the video?

• To raise awareness about all types of cancer

• To support research benefiting women with breast and ovarian cancer

• To fundraise for general medical research

• To promote healthy living through exercise

Which organizations are highlighted for their role in funding breast cancer research?

• American Cancer Society and WHO

• EIF and Revlon

• CDC and NIH

• Susan G. Komen and Avon

What significant change has occurred in the treatment outcomes for the HER2 subtype of breast cancer?

• Outcomes have improved from worst to best

• Outcomes have slightly improved

• Outcomes have worsened

• Outcomes have remained the same

What is the focus of the new therapy mentioned in the video?

• Triple-negative breast cancer

• Hormone-receptive breast cancer

• HER2-negative breast cancer

• Ovarian cancer

Why is it important to tailor therapy to the subtype of breast cancer a patient has?

• Because all subtypes respond the same way

• To minimize side effects

• To maximize the effectiveness of the treatment

• To ensure the therapy is cost-effective